Skip to main navigation Skip to search Skip to main content

Phase 1/2 Study of PF-06463922 (An ALK/ROS1 Tyrosine Kinase Inhibitor) in Patients with Advanced Non-Small Cell Lung Cancer Harboring Specific Molecular Alterations

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date07/14/15 → 07/13/23

Funding

  • Pfizer Incorporated: $610,996.87